text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 165800-06-6 | Product Number: Z0031

Zoledronic Acid Monohydrate

Purity: >98.0%(T)(HPLC)
  • 1-Hydroxy-2-(1-imidazolyl)ethane-1,1-diphosphonic Acid Monohydrate
6   ≥20 
2   10  

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).

Product Number Z0031
Purity / Analysis Method >98.0%(T)(HPLC)
Molecular Formula / Molecular Weight C__5H__1__0N__2O__7P__2·H__2O = 290.11  
Physical State (20 deg.C) Solid
Storage Temperature 0-10°C
Condition to Avoid Heat Sensitive
CAS RN 165800-06-6
Related CAS RN 118072-93-8
Reaxys Registry Number 9667036
PubChem Substance ID 253662255
Merck Index (14) 10187
MDL Number


Properties (reference)
Melting Point 245 °C(dec.)
Solubility in water Practically insoluble
Degree of solubility in water 7 g/l   25 °C
Solubility (insoluble in) Ethanol,Methanol
Pictogram Pictogram Pictogram
Signal Word Warning
Hazard Statements H315 : Causes skin irritation.
H319 : Causes serious eye irritation.
H361 : Suspected of damaging fertility or the unborn child.
Precautionary Statements P501 : Dispose of contents/ container to an approved waste disposal plant.
P201 : Obtain special instructions before use.
P264 : Wash skin thoroughly after handling.
P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection.
P308 + P313 : IF exposed or concerned: Get medical advice/ attention.
P337 + P313 : If eye irritation persists: Get medical advice/ attention.
Related Laws: / Compliance with laws, Regulations
RTECS# SZ8562450
Transport Information:
HS Number 2933299090
Bone Resorption Inhibitor

1)Bisphosphonates: From bench to bedside

R. Graham, G. Russell, Ann. N.Y. Acad. Sci. 2006, 1068, 367.

2)Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase

K. Ohno, K. Mori, M. Orita, M. Takeuchi, Curr. Med. Chem. 2011, 18, 220.

3)Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite

G. H. Nancollas, R. Tang, R. J. Phipps, Z. Henneman, S. Gulde, W. Wu, A. Mangood, R. G. G. Russell, F. H. Ebetino, Bone 2006, 38, 617.

4)Role of zoledronic acid in the prevention and treatment of osteoporosis

A. Räkel, A. Boucher, L.-G. Ste-Marie, Clin. Interv. Aging 2011, 6, 89.

5)Emerging strategies and therapies for treatment of Paget’s disease of bone

L. Michou, J. P. Brown, Drug Des. Devel. Ther. 2011, 5, 225.

6)The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy

P. Major, Oncologist 2002, 7, 481.

PubMed Literature

Safety Data Sheet (SDS) Search
Please select Language.

The requested SDS is not available.

• Please check that the Product Number you have entered is correct.

• If your information is correct and you are still not able to view the requested SDS,  please Contact Us for more information.

C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number is entered
Other Documents